Which has preferable earnings & valuation, DCGO or LFMD?

LifeMD has lower revenue, but higher earnings than DocGo. DocGo is trading at a lower price-to-earnings ratio than LifeMD, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DocGo $322.20M 0.17 -$182.40M -$1.91 N/A LifeMD $194.05M 1.22 $14.35M $0.05 97.80

Is DCGO or LFMD more profitable?

LifeMD has a net margin of 2.37% compared to DocGo's net margin of -62.23%. DocGo's return on equity of -44.09% beat LifeMD's return on equity. Company Net Margins Return on Equity Return on Assets DocGo -62.23% -44.09% -29.14% LifeMD 2.37% -150.88% -22.59%

Does the media refer more to DCGO or LFMD?

In the previous week, LifeMD had 2 more articles in the media than DocGo. MarketBeat recorded 3 mentions for LifeMD and 1 mentions for DocGo. DocGo's average media sentiment score of 0.00 beat LifeMD's score of -0.18 indicating that DocGo is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DocGo 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral LifeMD 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, DCGO or BDSX?

Biodesix has lower revenue, but higher earnings than DocGo. Biodesix is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DocGo $322.20M 0.17 -$182.40M -$1.91 N/A Biodesix $88.50M 1.81 -$35.26M -$4.06 N/A

Is DCGO or BDSX more profitable?

Biodesix has a net margin of -33.26% compared to DocGo's net margin of -62.23%. DocGo's return on equity of -44.09% beat Biodesix's return on equity. Company Net Margins Return on Equity Return on Assets DocGo -62.23% -44.09% -29.14% Biodesix -33.26% -2,101.40% -35.65%

Does the media refer more to DCGO or BDSX?

In the previous week, DocGo and DocGo both had 1 articles in the media. Biodesix's average media sentiment score of 1.19 beat DocGo's score of 0.00 indicating that Biodesix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DocGo 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Biodesix 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, XGN or DCGO?

Exagen has higher earnings, but lower revenue than DocGo. Exagen is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exagen $66.57M 1.56 -$19.95M -$0.89 N/A DocGo $322.20M 0.17 -$182.40M -$1.91 N/A

Is XGN or DCGO more profitable?

Exagen has a net margin of -29.49% compared to DocGo's net margin of -62.23%. DocGo's return on equity of -44.09% beat Exagen's return on equity. Company Net Margins Return on Equity Return on Assets Exagen -29.49% -94.37% -28.96% DocGo -62.23% -44.09% -29.14%

Does the media prefer XGN or DCGO?

In the previous week, Exagen and Exagen both had 1 articles in the media. Exagen's average media sentiment score of 0.00 equaled DocGo'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exagen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral DocGo 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, DCGO or NAKA?

KindlyMD has lower revenue, but higher earnings than DocGo. DocGo is trading at a lower price-to-earnings ratio than KindlyMD, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DocGo $322.20M 0.17 -$182.40M -$1.91 N/A KindlyMD $1.82M 41.21 -$52.23M -$43.20 N/A

Is DCGO or NAKA more profitable?

DocGo has a net margin of -62.23% compared to KindlyMD's net margin of -7,397.12%. DocGo's return on equity of -44.09% beat KindlyMD's return on equity. Company Net Margins Return on Equity Return on Assets DocGo -62.23% -44.09% -29.14% KindlyMD -7,397.12% -81.32% -54.17%

Do analysts prefer DCGO or BNR?

DocGo presently has a consensus price target of $2.38, indicating a potential upside of 324.71%. Given DocGo's stronger consensus rating and higher probable upside, analysts plainly believe DocGo is more favorable than Burning Rock Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DocGo 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33 Burning Rock Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

DocGo (DCGO) Competitors

$0.56 -0.01 (-1.91%)

Closing price 06/5/2026 04:00 PM Eastern

Extended Trading

$0.57 +0.01 (+1.57%)

As of 06/5/2026 07:58 PM Eastern

Compare

DCGO vs. LFMD, BDSX, XGN, NAKA, and BNR

Should you buy DocGo stock or one of its competitors? MarketBeat compares DocGo with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with DocGo include LifeMD (LFMD), Biodesix (BDSX), Exagen (XGN), KindlyMD (NAKA), and Burning Rock Biotech (BNR). These companies are all part of the "healthcare" industry.

How does DocGo compare to LifeMD?

DocGo (NASDAQ:DCGO) and LifeMD (NASDAQ:LFMD) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

DocGo presently has a consensus price target of $2.38, indicating a potential upside of 324.71%. LifeMD has a consensus price target of $9.14, indicating a potential upside of 86.97%. Given DocGo's higher probable upside, equities research analysts clearly believe DocGo is more favorable than LifeMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DocGo	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
LifeMD	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

LifeMD has lower revenue, but higher earnings than DocGo. DocGo is trading at a lower price-to-earnings ratio than LifeMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DocGo	$322.20M	0.17	-$182.40M	-$1.91	N/A
LifeMD	$194.05M	1.22	$14.35M	$0.05	97.80

In the previous week, LifeMD had 2 more articles in the media than DocGo. MarketBeat recorded 3 mentions for LifeMD and 1 mentions for DocGo. DocGo's average media sentiment score of 0.00 beat LifeMD's score of -0.18 indicating that DocGo is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DocGo	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
LifeMD	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

LifeMD has a net margin of 2.37% compared to DocGo's net margin of -62.23%. DocGo's return on equity of -44.09% beat LifeMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DocGo	-62.23%	-44.09%	-29.14%
LifeMD	2.37%	-150.88%	-22.59%

DocGo has a beta of 1, suggesting that its share price has a similar volatility profile to the broader market.Comparatively, LifeMD has a beta of 1.98, suggesting that its share price is 98% more volatile than the broader market.

56.4% of DocGo shares are held by institutional investors. Comparatively, 35.5% of LifeMD shares are held by institutional investors. 3.8% of DocGo shares are held by company insiders. Comparatively, 18.4% of LifeMD shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

LifeMD beats DocGo on 11 of the 16 factors compared between the two stocks.

How does DocGo compare to Biodesix?

DocGo (NASDAQ:DCGO) and Biodesix (NASDAQ:BDSX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk.

In the previous week, DocGo and DocGo both had 1 articles in the media. Biodesix's average media sentiment score of 1.19 beat DocGo's score of 0.00 indicating that Biodesix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DocGo	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Biodesix	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Biodesix has a net margin of -33.26% compared to DocGo's net margin of -62.23%. DocGo's return on equity of -44.09% beat Biodesix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DocGo	-62.23%	-44.09%	-29.14%
Biodesix	-33.26%	-2,101.40%	-35.65%

Biodesix has lower revenue, but higher earnings than DocGo. Biodesix is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DocGo	$322.20M	0.17	-$182.40M	-$1.91	N/A
Biodesix	$88.50M	1.81	-$35.26M	-$4.06	N/A

DocGo currently has a consensus target price of $2.38, suggesting a potential upside of 324.71%. Biodesix has a consensus target price of $22.00, suggesting a potential upside of 42.30%. Given DocGo's higher probable upside, equities research analysts clearly believe DocGo is more favorable than Biodesix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DocGo	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Biodesix	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

56.4% of DocGo shares are held by institutional investors. Comparatively, 21.0% of Biodesix shares are held by institutional investors. 3.8% of DocGo shares are held by insiders. Comparatively, 23.2% of Biodesix shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

DocGo has a beta of 1, indicating that its stock price has a similar volatility profile to the broader market.Comparatively, Biodesix has a beta of 0.59, indicating that its stock price is 41% less volatile than the broader market.

Summary

DocGo beats Biodesix on 9 of the 14 factors compared between the two stocks.

How does DocGo compare to Exagen?

Exagen (NASDAQ:XGN) and DocGo (NASDAQ:DCGO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.

75.3% of Exagen shares are held by institutional investors. Comparatively, 56.4% of DocGo shares are held by institutional investors. 10.4% of Exagen shares are held by company insiders. Comparatively, 3.8% of DocGo shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Exagen has higher earnings, but lower revenue than DocGo. Exagen is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exagen	$66.57M	1.56	-$19.95M	-$0.89	N/A
DocGo	$322.20M	0.17	-$182.40M	-$1.91	N/A

Exagen currently has a consensus price target of $9.25, indicating a potential upside of 115.62%. DocGo has a consensus price target of $2.38, indicating a potential upside of 324.71%. Given DocGo's higher possible upside, analysts plainly believe DocGo is more favorable than Exagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exagen	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78
DocGo	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Exagen has a beta of 2.02, meaning that its share price is 102% more volatile than the broader market. Comparatively, DocGo has a beta of 1, meaning that its share price has a similar volatility profile to the broader market.

In the previous week, Exagen and Exagen both had 1 articles in the media. Exagen's average media sentiment score of 0.00 equaled DocGo'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exagen	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
DocGo	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Exagen has a net margin of -29.49% compared to DocGo's net margin of -62.23%. DocGo's return on equity of -44.09% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exagen	-29.49%	-94.37%	-28.96%
DocGo	-62.23%	-44.09%	-29.14%

Summary

Exagen beats DocGo on 10 of the 14 factors compared between the two stocks.

How does DocGo compare to KindlyMD?

DocGo (NASDAQ:DCGO) and KindlyMD (NASDAQ:NAKA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability, media sentiment and earnings.

DocGo currently has a consensus target price of $2.38, suggesting a potential upside of 324.71%. KindlyMD has a consensus target price of $30.00, suggesting a potential upside of 596.06%. Given KindlyMD's stronger consensus rating and higher possible upside, analysts clearly believe KindlyMD is more favorable than DocGo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DocGo	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
KindlyMD	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

56.4% of DocGo shares are owned by institutional investors. 3.8% of DocGo shares are owned by insiders. Comparatively, 24.5% of KindlyMD shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, DocGo had 1 more articles in the media than KindlyMD. MarketBeat recorded 1 mentions for DocGo and 0 mentions for KindlyMD. DocGo's average media sentiment score of 0.00 equaled KindlyMD'saverage media sentiment score.

Company	Overall Sentiment
DocGo	Neutral
KindlyMD	Neutral

DocGo has a net margin of -62.23% compared to KindlyMD's net margin of -7,397.12%. DocGo's return on equity of -44.09% beat KindlyMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DocGo	-62.23%	-44.09%	-29.14%
KindlyMD	-7,397.12%	-81.32%	-54.17%

DocGo has a beta of 1, suggesting that its share price has a similar volatility profile to the broader market.Comparatively, KindlyMD has a beta of 15.84, suggesting that its share price is 1,484% more volatile than the broader market.

KindlyMD has lower revenue, but higher earnings than DocGo. DocGo is trading at a lower price-to-earnings ratio than KindlyMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DocGo	$322.20M	0.17	-$182.40M	-$1.91	N/A
KindlyMD	$1.82M	41.21	-$52.23M	-$43.20	N/A

Summary

DocGo and KindlyMD tied by winning 7 of the 14 factors compared between the two stocks.

How does DocGo compare to Burning Rock Biotech?

DocGo (NASDAQ:DCGO) and Burning Rock Biotech (NASDAQ:BNR) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, risk, valuation, institutional ownership, analyst recommendations and earnings.

DocGo has a beta of 1, indicating that its share price has a similar volatility profile to the broader market.Comparatively, Burning Rock Biotech has a beta of 1.32, indicating that its share price is 32% more volatile than the broader market.

In the previous week, DocGo had 1 more articles in the media than Burning Rock Biotech. MarketBeat recorded 1 mentions for DocGo and 0 mentions for Burning Rock Biotech. DocGo's average media sentiment score of 0.00 equaled Burning Rock Biotech'saverage media sentiment score.

Company	Overall Sentiment
DocGo	Neutral
Burning Rock Biotech	Neutral

56.4% of DocGo shares are held by institutional investors. Comparatively, 30.0% of Burning Rock Biotech shares are held by institutional investors. 3.8% of DocGo shares are held by insiders. Comparatively, 30.3% of Burning Rock Biotech shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Burning Rock Biotech has a net margin of -10.27% compared to DocGo's net margin of -62.23%. Burning Rock Biotech's return on equity of -9.98% beat DocGo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DocGo	-62.23%	-44.09%	-29.14%
Burning Rock Biotech	-10.27%	-9.98%	-6.69%

DocGo presently has a consensus price target of $2.38, indicating a potential upside of 324.71%. Given DocGo's stronger consensus rating and higher probable upside, analysts plainly believe DocGo is more favorable than Burning Rock Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DocGo	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Burning Rock Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Burning Rock Biotech has lower revenue, but higher earnings than DocGo. Burning Rock Biotech is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DocGo	$322.20M	0.17	-$182.40M	-$1.91	N/A
Burning Rock Biotech	$77.16M	1.26	-$7.92M	-$0.79	N/A

Summary

Burning Rock Biotech beats DocGo on 8 of the 15 factors compared between the two stocks.

Get DocGo News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DCGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DCGO vs. The Competition

Export

Metric	DocGo	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$55.22M	$8.70B	$6.68B	$11.99B
Dividend Yield	N/A	1.76%	2.67%	5.55%
P/E Ratio	-0.29	22.29	24.06	23.63
Price / Sales	0.17	20.38	519.33	112.45
Price / Cash	10.11	88.45	42.23	54.60
Price / Book	0.44	5.20	9.73	6.35
Net Income	-$182.40M	$175.77M	$3.57B	$337.59M
7 Day Performance	-15.02%	-2.20%	-1.28%	-2.52%
1 Month Performance	-11.78%	7.06%	1.38%	-0.03%
1 Year Performance	-63.45%	3.44%	23.93%	25.34%

DocGo Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DCGO DocGo	2.902 of 5 stars	$0.56 -1.9%	$2.38 +324.7%	-63.5%	$55.22M	$322.20M	N/A	3,568
LFMD LifeMD	3.2917 of 5 stars	$4.28 -6.8%	$9.14 +113.6%	-61.6%	$206.98M	$194.05M	85.62	230	News Coverage
BDSX Biodesix	3.5723 of 5 stars	$16.32 +2.1%	$22.00 +34.8%	+155.2%	$169.08M	$88.50M	N/A	220	News Coverage Positive News
XGN Exagen	3.4573 of 5 stars	$4.98 -2.0%	$9.25 +85.7%	-40.8%	$120.32M	$66.57M	N/A	220	Gap Down
NAKA KindlyMD	3.1675 of 5 stars	$6.26 +11.8%	$30.00 +379.2%	N/A	$108.92M	$1.82M	N/A	N/A	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DCGO) was last updated on 6/7/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

DocGo (DCGO) Competitors